Heron Therapeutics Files 8-K
Ticker: HRTX · Form: 8-K · Filed: 2024-05-29T00:00:00.000Z
Sentiment: neutral
Topics: sec-filing, regulation-fd, financial-reporting
Related Tickers: HRTX
TL;DR
HERON THERAPEUTICS FILES STANDARD 8-K REPORTING REG FD DISCLOSURE AND EXHIBITS.
AI Summary
Heron Therapeutics, Inc. filed an 8-K on May 29, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or new material events beyond the standard reporting requirements for this form type.
Why It Matters
This filing indicates Heron Therapeutics is adhering to its reporting obligations with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — This is a routine filing that does not disclose new material information or significant financial events.
Key Players & Entities
- Heron Therapeutics, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- May 29, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is May 29, 2024.
What is the company's exact name as specified in its charter?
The company's exact name is Heron Therapeutics, Inc.
In which state is Heron Therapeutics, Inc. incorporated?
Heron Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address of Heron Therapeutics, Inc.?
The principal executive office address is 4242 Campus Point Court, Suite 200, San Diego, CA 92121.
Filing Stats: 528 words · 2 min read · ~2 pages · Grade level 9.7 · Accepted 2024-05-29 08:05:11
Key Financial Figures
- $0.01 — ch registered Common Stock, par value $0.01 per share HRTX The Nasdaq Capital M
Filing Documents
- hrtx-20240529.htm (8-K) — 47KB
- hrtx-ex99_1.htm (EX-99.1) — 21KB
- 0000950170-24-065636.txt ( ) — 193KB
- hrtx-20240529.xsd (EX-101.SCH) — 30KB
- hrtx-20240529_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On May 29, 2024, Heron Therapeutics, Inc. issued a press release announcing that it had submitted to the U.S. Food and Drug Administration the Prior Approval Supplement for ZYNRELEF (bupivacaine and meloxicam) extended-release solution Vial Access Needle, as further described in the press release. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference in this Item 7.01. As provided in General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall such information or Exhibit 99.1 be deemed to be incorporated by reference in any filing under the Securities Act, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated May 29, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Heron Therapeutics, Inc. Date: May 29, 2024 /s/ Ira Duarte Ira Duarte Executive Vice President, Chief Financial Officer